ViiV claims $1.25bn settlement from Gilead in HIV patent dispute
pharmaphorum
FEBRUARY 2, 2022
billion settlement as well as royalties on sales of one of its top HIV products. Along with the one-off settlement, Gilead has agreed to pay ViiV a 3% royalty rate on Biktarvy sales and any other bictegravir-containing product in the US until 5 October 2027, when ViiV’s US patent on dolutegravir expires. Revenue fall.
Let's personalize your content